期刊文献+

静脉铁剂在肾性贫血中的治疗作用 被引量:1

Effect of intravenous ferralia on renal anemic
下载PDF
导出
摘要 目的观察右旋糖酐铁静脉注射治疗尿毒症致肾性贫血的疗效和不良反应。方法80例尿毒症血液透析病人随机分为两组。对照组:速立菲200 mg,每日3次,口服。治疗组:右旋糖酐铁100 mg,每周1次,静脉滴注。两组均治疗10周,并同时应用促红细胞生成素(EPO)9 000U/周。结果对照组治疗后血红蛋白(Hb)、红细胞压积(Hct)较治疗前有明显升高(P<0.01),但转铁蛋白饱和度(TSAT)、铁蛋白(FT)与治疗前对比无明显提高(P>0.05)。治疗组治疗后Hb、Hct、TSAT、FT较治疗前均有显著升高(P<0.001)。两组治疗后的Hb、Hct、TSAT、FT对比,治疗组比对照组有显著升高(P<0.001)。结论静脉注射铁剂能有效补充EPO治疗中所需要的铁储备,疗效优于口服,不良反应少。 Objective To investigate the curative effect and untoward effect of intravenous therapy with iron dextran for renal anemia induced by uremia. Methods Eighty patients of uremia for hemodialysis were divided into two groups randomly. Forty patients who took ferrous sueeinate tablets for 200 mg three times a day orally were regarded as the controls. The other forty patients who received intravenous therapy with iron dextran for 100 mg once a week were enrolled in this study as the treamaent group. Both groups were treated as long as 10 weeks. Results In the controls, the hemoglobin (Hb) levels after the therapy were significantly higher than that before the thrapy( P 〈 0. O1 ). But the heamatocrit (Hct), transferrin saturation (TSAT), ferritin (FT) levels were not significantly higher than that before the therapy ( P 〉 0. 05 ). In the treatment group, Hb, Hct, TSAT, FT after the therapy were all significantly higher than that before the therapy ( P 〈 0.001 ). In the treatment group, Hb, Hct, TSAT, FT after the therapy were significantly higher than that in the controls ( P 〈 0.001). Conclusion Intravenous therapy with ferralia can keep sutficient iron stores needed duning erythopoietin treatment. It is quiclily up to the standard for file treatment for anemia,and associated with skimp untoward effect.
出处 《医师进修杂志》 2005年第9期25-26,共2页 Journal of Postgraduates of Medicine
  • 相关文献

参考文献3

  • 1Feldman HI, Santanna J, Guo W, et al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol,2002, 13:734 -744.
  • 2Agarwal R, Warnock D. Lssues related to iron replacement in chronsic kidney disease. Semin Nephrol,2002,22:479 - 487.
  • 3王海燕 王梅主译.慢性肾脏病及透析的临床实践指南[M].北京:人民卫生出版社,2003.46-471.

共引文献80

同被引文献19

  • 1范敏华.静脉铁的临床应用[J].中国血液净化,2006,5(8):407-409. 被引量:26
  • 2葛永纯,谢红浪.肾性贫血治疗中静脉铁剂的应用[J].肾脏病与透析肾移植杂志,2007,16(2):178-181. 被引量:9
  • 3Hoen B;Kessller M;Hestin D.Risk factors for bacterial infections in chronic hemodialysis adult patients.A multicentre prospective survey,1995(10).
  • 4Bullen JJ;Word CG;Wallis SN.Virulence and the role of iron in Pseudomonas aeruginosa infection,1974(10).
  • 5Michael B;Coyne DW;Fishbane S.Sodium ferric gluconate complex in hemodialysis patients,2002(61).
  • 6Ganz T.Hepcidina regulator of intestinal iron recycling by macrophages,2005(18).
  • 7Kalantar-Zadeh K;Rodriguez RA;Humphreys MH.Association between serum ferritin and measures of inflammation,nutrition and iron in hemodialysis patients,2004(19).
  • 8Ervasti M;Kotisaari S;Romppanen J.In patients who have stainable iron in the bone marrow an elevated plasma transferring receptor value may reflect functional iron deficiency,2004(26).
  • 9Skikne BS;Ahluwalia N;Fergusson B.Effects of erythropoietin therapy on iron absorption in chronic renal failure,2000(135).
  • 10Longnecker RE;Goffinet JA;Hendler ED.Blood loss during maintenance hemodialysis,1974(20).

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部